ArticleCurrent oncology (Toronto, Ont.)2026
Efficacy of Lenvatinib as Second-Line Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Daichi Takizawa, Hirotaka Arai, Mitsuhiko Shibasaki, Yuki Tamura, Satoru Kakizaki, Takeshi Hatanaka, Atsushi Naganuma, Takashi Ueno, Toru Fukuchi, Masashi Namikawa and 6 more
Abstract read
In one paragraphArticle in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Daichi TakizawaDepartment of Gastroenterology, Maebashi Red Cross Hospital, Maebashi 371-0811, Japan.ORCID 0000-0002-2004-8285 Hirotaka AraiDepartment of Gastroenterology, Maebashi Red Cross Hospital, Maebashi 371-0811, Japan.
Mitsuhiko ShibasakiDepartment of Gastroenterology, Maebashi Red Cross Hospital, Maebashi 371-0811, Japan.
Yuki TamuraDepartment of Gastroenterology, Maebashi Red Cross Hospital, Maebashi 371-0811, Japan.
Satoru KakizakiDepartment of Clinical Research, NHO Takasaki General Medical Center, Takasaki 370-0829, Japan.ORCID 0000-0003-0224-7093 Takeshi HatanakaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi 371-0821, Japan.ORCID 0000-0003-3656-285X Atsushi NaganumaDepartment of Gastroenterology, NHO Takasaki General Medical Center, Takasaki 370-0829, Japan.ORCID 0000-0003-0663-0102 Takashi UenoDepartment of Internal Medicine, Isesaki Municipal Hospital, Isesaki 372-0817, Japan.
Toru FukuchiDepartment of Internal Medicine, Kiryu Kosei General Hospital, Kiryu 376-0024, Japan.
Masashi NamikawaDepartment of Gastroenterology, Subaru Health Insurance Society Ota Memorial Hospital, Ota 373-8585, Japan.
Satoshi TakakusagiDepartment of Gastroenterology and Hepatology, Kusunoki Hospital, Fujioka 375-0024, Japan.ORCID 0000-0002-4366-1699 Shuichi SaitoDepartment of Gastroenterology, Public Tomioka General Hospital, Tomioka 370-2393, Japan.
Takayoshi SugaDepartment of Gastroenterology, NHO Shibukawa Medical Center, Shibukawa 377-0280, Japan.
Hiroki TojimaDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan.
Yuichi YamazakiDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan.ORCID 0000-0002-8633-2983 Toshio UraokaDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan.ORCID 0000-0002-4425-4331 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsQuinolinesAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedatezolizumabBevacizumablenvatinibPhenylurea CompoundsQuinolinesatezolizumabbevacizumabhepatocellular carcinomalenvatinibsecond-line
Identifiers
PMID41892187
PMCPMC13025887
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390